Novartis Oncology CEO Bruno Strigini to Retire

By Marc Bisbal AriasFeaturesDow Jones Newswires

Novartis AG (NOVN.EB) said Friday that Bruno Strigini, chief executive officer at Novartis Oncology, has decided to retire from the company and the industry due to personal reasons.

Mr. Strigini will step back from the executive committee of Novartis by Dec. 31. and complete the handover in early 2018, the Swiss company said.

Continue Reading Below

Chief Executive Joseph Jimenez thanked Mr. Strigini for his contributions and achievements, citing the successful integration of the GSK oncology-product portfolio that it acquired in 2015, and which he led.

His successor will be announced in due time, it added.

Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com

(END) Dow Jones Newswires

December 15, 2017 01:33 ET (06:33 GMT)